CN105412023A - Frovatriptan succinate controlled-release granule and preparation method thereof - Google Patents
Frovatriptan succinate controlled-release granule and preparation method thereof Download PDFInfo
- Publication number
- CN105412023A CN105412023A CN201510886855.3A CN201510886855A CN105412023A CN 105412023 A CN105412023 A CN 105412023A CN 201510886855 A CN201510886855 A CN 201510886855A CN 105412023 A CN105412023 A CN 105412023A
- Authority
- CN
- China
- Prior art keywords
- succinic acid
- acid furan
- smooth
- release
- luo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Abstract
The invention discloses a frovatriptan succinate controlled-release granule, which is prepared by controlled-release coating an inner core which is prepared from frovatriptan succinate by virtue of an inclusion technology. The invention also discloses a preparation method of the frovatriptan succinate controlled-release granule. Compared with the prior art, the controlled-release granule disclosed by the invention can slowly release drugs at a constant speed in a specified release medium, so that the release degree and the bioavailability of the frovatriptan succinate are effectively improved; the controlled-release granule can achieve rapid release to cause efficacy in the initial stage of medication and can realize slow release at the constant speed in the later stage so as to keep a normal blood concentration, therefore the efficacy is kept for a long time without the generation of toxic or side effects or intoxication due to drug accumulation, the curative effect is improved and the controlled-release is safe and rapid. Meanwhile, the preparation method of the invention is applicable to expanded production.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to smooth controlled release granule of a kind of succinic acid furan Luo Qu and preparation method thereof.
Background technology
Migraine is clinical modal primary headache type; clinical with ictal middle severe, sample of beating headache for main manifestations; headache mostly is inclined side; general lasting 4-72 hour; can with Nausea and vomiting; light, Sound stimulat or daily routines all can increase the weight of headache, and quiet environment, rest can alleviate headache.Migraine is a kind of common chronic forms vascular illness, and a lot of disease is in child and adolescence, and the young and middle-aged phase reaches onset peak, and women is common, and in crowd, prevalence is 5%-10%, often has genetic background.
Migraine is primary in central nervous system function disorder, and Vascular change is secondary, disorderly with neurotransmitter numerous in blood and cerebrospinal fluid during migraine.Someone also proposes neurogenic inflammation and causes migraine, thinks that cause the neurogenic inflammation of cerebral dura mater and institute's Supply Organization thereof, its main manifestations is plasma protein extravasation and vasodilation by stimulating nervi trigeminus peripheral vessels fiber to discharge vasoactive peptide.Recent research finds that the NO be present in central nervous system plays an important role to the transmission of pain stimulation at maincenter.But what receive much attention in recent years is trigemino-vascular reflex theory, nerve, blood vessel and neurotransmitter triplicity is got up, and is unified in trigeminal vascular system.This hypothesis is thought by stimulating some specific region in brain, causes the outer vasodilation of cranium and internal carotid artery vasodilation, produce headache through series reaction.In the process, the 5-HT of intra platelet free calcium enhances the sensitivity of vascular receptor, plays an important role to the generation of pain.Some the migrainous clinical manifestations of this hypothesis well explain, were used for the treatment of migraine provided rational explanation for some have both acted on medicine that nervus centralis nervous system also acts on peripheral nervous system.
Succinic acid furan sieve Qu Tan is the in vitro cerebral vasoconstriction agent of multiple species (comprising people).Arterial Rings In Vitro blood vessel observes the activity of succinic acid furan sieve Qu Tan as vasoconstrictor, and compares with sumatriptan.On people's middle cerebral artery, succinic acid furan sieve Qu Tan is a kind of partial agonist (relative to 5-HT), and effect is at least 5 times of sumatriptan.Succinic acid furan sieve Qu Tan is a kind of full agonists to people's basilar artery, and its effect is about 8.3 times of sumatriptan.The effect of succinic acid furan sieve Qu Tan to rabbit basilar artery and cat brain medium-sized artery is 23 and 3 times of sumatriptan respectively.Rabbit, compared with 5-HT, succinic acid furan sieve Qu Tan is a kind of partial agonist, and sumatriptan is a kind of full agonist.Cat, relative to 5-HT, succinic acid furan sieve Qu Tan and sumatriptan are all partial agonists.
Summary of the invention
Current China market mainly contains the oral tablet of succinic acid furan sieve Qu Tan, tablet and injection, although oral tablet and tablet taking convenience, but be subject to the impact of the factor such as disintegrate, drug release, assimilation effect is undesirable, and although injection curative effect is fast, but carry, use all inconveniences, and succinic acid furan sieve Qu Tan is also unstable in aqueous.
In recent years, the research and development of controlled release granule come into one's own gradually, and controlled release granule is that release by time effects constant release, can not obtain more stable blood drug level by the release of zero-order rule, and " peak valley " fluctuation is less, until basic absorption is complete.Controlled release granule can make patient reduce medicining times, administration frequency reduces half than ordinary preparation, facilitate patient's Long-term taking medicine, significantly improve the compliance of patient consumes, by the control of drug release rate, medicine slowly absorbs with suitable speed, make blood drug level steady, avoid or reduce peak valley phenomenon, contribute to the toxic and side effects and the raising curative effect that reduce medicine, reduce medicine at gastrointestinal local concentration, reduce zest.
In order to overcome the deficiencies in the prior art, the present invention to adjuvant screening and process optimization, provides the smooth controlled release granule of a kind of succinic acid furan Luo Qu, this controlled release granule steady quality by lot of experiments, and drug release is even, and preparation technology is simple.
for achieving the above object, the technical scheme taked of the present invention:
The technical problem to be solved in the present invention is to provide the smooth controlled release granule of a kind of succinic acid furan Luo Qu, with the problem that the clinical effectiveness solving the existence of existing succinic acid furan Luo Qu smooth product is not good.
The technical problem that the present invention also will solve is to provide the preparation method of the smooth controlled release granule of above-mentioned succinic acid furan Luo Qu.
For solving the problems of the technologies described above, the technical solution used in the present invention is as follows:
The smooth controlled release granule of a kind of succinic acid furan Luo Qu, it comprises the smooth inner core of succinic acid furan Luo Qu and controlled release peplos from the inside to the outside;
Wherein, the mass ratio of controlled release peplos and the smooth inner core of succinic acid furan Luo Qu is 6 ~ 15:100(solid content ratio);
(1) controlled release peplos comprises the component of following parts by weight:
Coating solution Sulisi E-7-19040100 part
Porogen hypromellose E55 ~ 8 part
(2) the smooth inner core of succinic acid furan Luo Qu comprises the component of following parts by weight:
Smooth 1 part of succinic acid furan Luo Qu
Beta-schardinger dextrin-2 ~ 5 parts
Ethyl cellulose 0.2 ~ 1 part
Sodium carboxymethyl cellulose 0.02 ~ 0.1 part
1 ~ 3 part, water
The preparation method of the smooth controlled release granule of above-mentioned succinic acid furan Luo Qu, it comprises the steps:
(1) by beta-schardinger dextrin-and water mixing post-heating to 60 ~ 90 DEG C, add succinic acid furan sieve Qu Tan, stir 30 ~ 60min;
(2) mixed system obtained in step (1) is carried out spraying dry by spray drying tower, obtain the smooth soluble powder of succinic acid furan Luo Qu;
(3) after the smooth soluble powder of succinic acid furan Luo Qu, ethyl cellulose and the sodium carboxymethyl cellulose that obtain in step (2) being mixed, centrifugal granulation and fluidized coating method is granulated, dry, sift out the granule of 40 ~ 60 order particle diameters, obtain the smooth inner core of succinic acid furan Luo Qu;
(4) coating solution Sulisi E-7-19040 is atomization in aerochamber after mixing homogeneously with hypromellose after diluting, and is sprayed at the smooth core surface of succinic acid furan Luo Qu of the middle gained of step (3), obtains the smooth controlled release granule of succinic acid furan Luo Qu.
Wherein, in step (1), the mass ratio of beta-schardinger dextrin-and succinic acid furan sieve Qu Tan is 2 ~ 5:1.
Wherein, in step (2), inlet temperature is 160 ~ 200 DEG C, and aspiration pressure is 0.3 ~ 0.4Mpa, leaving air temp 75 ~ 95 DEG C.
Wherein, in step (3), bake out temperature is 40 ~ 80 DEG C, and drying time is 1 ~ 3h.
Wherein, in step (4), the mass ratio of coating solution Sulisi E-7-19040 and thinned water is 2:3.
compared with prior art, the present invention has following advantage:
1. first the present invention adopts cyclodextrin inclusion technique effectively to improve dissolubility and the bioavailability of succinic acid furan sieve Qu Tan, solubility experiment shows, under room temperature, the smooth crude drug dissolubility of succinic acid furan Luo Qu is less than 300ppm, and after forming clathrate, dissolubility reaches 3000ppm.The smooth area under the drug-time curve of succinic acid furan Luo Qu obviously increases, and shows that bioavailability improves.
2. the controlled release granule prepared of the present invention is using the smooth clathrate of succinic acid furan Luo Qu as granule ball core, using ethyl cellulose and hypromellose mixing as thin film coating material.Ethyl cellulose has outstanding sustained release performance, stops burst drug release; A small amount of hypromellose forms hydrophilic channel on coating membrane, helps enough the discharging from granule interior lastingly of medicine.By the release characteristics regulating the ratio of two kinds of coating materials to control medicine.
3. present invention incorporates the double technique of cyclodextrin inclusion technique and controlled release coat, the smooth controlled release granule of succinic acid furan Luo Qu of preparation can discharge rapidly at the initial stage of taking and produce drug effect, and the later stage slowly steadily discharges, and maintains drug effect for a long time and does not produce toxicity.
4. the material safety of the present invention's use is high, is easy to buy.The spray drying technology adopted and centrifugal granulation and fluidized coating technology are suitable for extension and produce.
Detailed description of the invention
According to following embodiment, the present invention may be better understood.But those skilled in the art will readily understand, the content described by embodiment only for illustration of the present invention, and should can not limit the present invention described in detail in claims yet.
embodiment 1
The smooth 3.91g of succinic acid furan Luo Qu
Beta-schardinger dextrin-106g
Ethyl cellulose 6.62g
Sodium carboxymethyl cellulose 0.66g
Sulisi E-7-1904021.33g
Hypromellose E50.26g
Purified Water q. s
Concrete preparation method is as follows:
(1) get appropriate purified water and be heated to 80 DEG C, add beta-schardinger dextrin-stirring and dissolving, then add succinic acid furan sieve Qu Tan, stir 30min, form the smooth solution of succinic acid furan Luo Qu;
(2) adjustable spraying exsiccator inlet temperature 160 DEG C, leaving air temp 80 DEG C, pressure 0.3MPa, carries out spraying dry by the smooth solution of above-mentioned succinic acid furan Luo Qu, obtains the smooth soluble powder of succinic acid furan Luo Qu;
(3) get the smooth soluble powder of 66.25g above-mentioned succinic acid furan Luo Qu, ethyl cellulose, sodium carboxymethyl cellulose mixing, add 26.47g water, mix soft material processed;
(4) centrifugal granulation and fluidized coating method is granulated, and 60 DEG C are dried 2h, screening 40 ~ 60 object granules;
(5) Sulisi E-7-19040 dilute with water is mixed homogeneously with hydroxypropyl cellulose E5 again form coating solution; Get the inner core 56g that (4) prepare, be placed in fluidisation in fluid bed, after coating solution atomization, even application is in ball wicking surface, obtains the smooth controlled release granule of succinic acid furan Luo Qu.
embodiment 2
The smooth 3.91g of succinic acid furan Luo Qu
Beta-schardinger dextrin-106g
Ethyl cellulose 6.62g
Sodium carboxymethyl cellulose 0.662g
Sulisi E-7-1904017.07g
Hypromellose E50.21g
Purified Water q. s
concrete preparation method is as embodiment 1.
embodiment 3
The smooth 3.91g of succinic acid furan Luo Qu
Beta-schardinger dextrin-96g
Ethyl cellulose 8.31g
Sodium carboxymethyl cellulose 0.332g
Sulisi E-7-1904024.81g
Hypromellose E50.49g
Purified Water q. s
Concrete preparation method is as embodiment 1.
embodiment 4
The smooth 3.91g of succinic acid furan Luo Qu
Beta-schardinger dextrin-96g
Ethyl cellulose 6.62g
Sodium carboxymethyl cellulose 0.662g
Sulisi E-7-1904017.5g
Hypromellose E50.21g
Purified Water q. s
concrete preparation method is as embodiment 1.
embodiment 5
The smooth 3.91g of succinic acid furan Luo Qu
Beta-schardinger dextrin-96g
Ethyl cellulose 8.31g
Sodium carboxymethyl cellulose 0.662g
Sulisi E-7-1904021.33g
Hypromellose E50.21g
Purified Water q. s
Concrete preparation method is as embodiment 1.
comparing embodiment 1
The smooth 3.91g of succinic acid furan Luo Qu
Ethyl cellulose 8.31g
Sodium carboxymethyl cellulose 0.662g
Sulisi E-7-1904021.33g
Hypromellose E50.21g
Purified Water q. s
Concrete preparation method is as embodiment 1.
comparing embodiment 2
The smooth 3.91g of succinic acid furan Luo Qu
Beta-schardinger dextrin-96g
Sodium carboxymethyl cellulose 0.662g
Sulisi E-7-1904021.33g
Hypromellose E50.21g
Purified Water q. s
Concrete preparation method is as embodiment 1.
comparing embodiment 3
The smooth 3.91g of succinic acid furan Luo Qu
Beta-schardinger dextrin-96g
Ethyl cellulose 8.31g
Sulisi E-7-1904021.33g
Hypromellose E50.21g
Purified Water q. s
Concrete preparation method is as embodiment 1.
test example 1the assay of long-term stable experiment
Intend listing sample and be placed on temperature 25 DEG C, relative humidity 60% time 36 months, high performance liquid chromatography (" Chinese Pharmacopoeia " 2015 editions four general rules 0512) is adopted to measure respectively at sampling when 0,3,6,12,24 and 36 months, adopt external standard method to calculate content, the results are shown in Table 1.Result shows that the stability of active component succinic acid furan sieve Qu Tan in the smooth controlled release granule of succinic acid furan Luo Qu of the present invention is obviously better than comparing embodiment.Table 1 is as follows:
test example 2bioavailability study
Oral administration is carried out to 4 beasle dogs (being male), feed with the smooth controlled release granule of succinic acid furan Luo Qu of the embodiment of the present invention 5, comparing embodiment 1, comparing embodiment 2, comparing embodiment 3 (temperature 25 DEG C, relative humidity are placed 12 months for 60% time) respectively to them, dosage only (smooth in succinic acid furan Luo Qu) is 10.0 μ g/, and the interval time of each administration is 7 days.After giving medicine, blood sample collection under different time, and carry out the smooth maximum haemoconcentration (C of succinic acid furan Luo Qu
max) and bioavailability (AUC
0 → 48) calculating.Acquisition time is 0h, 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h, 24h, 32h, 48h.
Table 2 provides the average result of the smooth controlled release granule gained of succinic acid furan Luo Qu 4 beasle dogs being given to the embodiment of the present invention 5, comparing embodiment 1, comparing embodiment 2, comparing embodiment 3.As seen from table, the smooth maximum haemoconcentration of succinic acid furan Luo Qu of the smooth controlled release granule of succinic acid furan Luo Qu of the present invention (embodiment 5) and bioavailability are apparently higher than comparing embodiment.
Should be noted that; the foregoing is only preferred embodiment of the present invention; be not limited to scope of the present invention, every any amendment done within the spirit and principles in the present invention, equivalent replacement and improvement etc., all should be included within protection scope of the present invention.
test example 3vitro release is tested
Measure according to dissolution and drug release determination method (" Chinese Pharmacopoeia " 2015 editions four general rule 0931 first methods), analogue body digested road condition, temperature controls at 37 DEG C ± 0.5 DEG C, with degassed fresh purified water for release medium, dilute hydrochloric acid (0.001 ~ 0.1mol/L) is used to carry out drug release rate test to the smooth controlled release granule of succinic acid furan Luo Qu, respectively 1,2,4,6,8,12h sampling, according to ultraviolet visible spectrophotometry (" Chinese Pharmacopoeia " 2015 editions four general rules 0401), measure absorbance, calculate accumulative releasing degree according to standard curve.Table 3 is as follows:
Can find out, the smooth controlled release granule of succinic acid furan Luo Qu obtained by the inventive method can constant speed, evenly discharge, the medicine effective blood drug concentration that can maintain the long period is described, reduce medicining times; Wherein the smooth controlled release granule of succinic acid furan Luo Qu of embodiment 5 discharged evenly in 12 hours, can reach higher release, be obviously better than comparing embodiment at the 12nd hour.Illustrate the smooth controlled release granule of succinic acid furan Luo Qu of the present invention can in the release medium of regulation constant release medicine lentamente, effectively improve release and the bioavailability of the smooth controlled release granule of succinic acid furan Luo Qu, generation drug effect can be discharged rapidly at the initial stage of taking, later stage is constant release lentamente, maintain normal blood drug level, long-time maintenance drug effect and do not produce toxicity, do not cause drug accumulation poisoning, improves curative effect, safety quick.Meanwhile, the preparation method in the inventive method is suitable for extension and produces.
Claims (6)
1. the smooth controlled release granule of succinic acid furan Luo Qu, is characterized in that, it comprises the smooth inner core of succinic acid furan Luo Qu and controlled release peplos from the inside to the outside; Wherein, the mass ratio of controlled release peplos and the smooth inner core of succinic acid furan Luo Qu is 6 ~ 15:100;
(1) controlled release peplos comprises the component of following parts by weight:
Coating solution Sulisi E-7-19040100 part
Porogen hypromellose E55 ~ 8 part
(2) the smooth inner core of succinic acid furan Luo Qu comprises the component of following parts by weight:
Smooth 1 part of succinic acid furan Luo Qu
Beta-schardinger dextrin-2 ~ 5 parts
Ethyl cellulose 0.2 ~ 1 part
Sodium carboxymethyl cellulose 0.02 ~ 0.1 part
1 ~ 3 part, water.
2., according to the preparation method of the smooth controlled release granule of succinic acid furan Luo Qu according to claim 1, it is characterized in that, comprise the steps:
(1) by beta-schardinger dextrin-and water mixing post-heating to 60 ~ 90 DEG C, add succinic acid furan sieve Qu Tan, stir 30 ~ 60min;
(2) mixed system obtained in step (1) is carried out spraying dry by spray drying tower, obtain the smooth soluble powder of succinic acid furan Luo Qu;
(3), after the smooth soluble powder of succinic acid furan Luo Qu, ethyl cellulose and the sodium carboxymethyl cellulose that obtain in step (2) being mixed, centrifugal granulation and fluidized coating method is granulated, and after oven dry, obtains the smooth inner core of succinic acid furan Luo Qu;
(4) atomization in aerochamber after mixing homogeneously with porogen hypromellose E5 after coating solution Sulisi E-7-19040 dilute with water, and be sprayed at the smooth core surface of succinic acid furan Luo Qu of the middle gained of step (3).
3. according to preparation method according to claim 2, it is characterized in that, in step (1), the mass ratio of beta-schardinger dextrin-and succinic acid furan sieve Qu Tan is 2 ~ 5:1.
4. according to preparation method according to claim 2, it is characterized in that, in step (2), inlet temperature is 160 ~ 200 DEG C, and aspiration pressure is 0.3 ~ 0.4Mpa, leaving air temp 75 ~ 95 DEG C.
5. according to preparation method according to claim 2, it is characterized in that, in step (3), bake out temperature is 40 ~ 80 DEG C, and drying time is 1 ~ 3h.
6. according to preparation method according to claim 2, it is characterized in that, in step (4), the mass ratio of coating solution Sulisi E-7-19040 and thinned water is 2:3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510886855.3A CN105412023A (en) | 2015-12-07 | 2015-12-07 | Frovatriptan succinate controlled-release granule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510886855.3A CN105412023A (en) | 2015-12-07 | 2015-12-07 | Frovatriptan succinate controlled-release granule and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105412023A true CN105412023A (en) | 2016-03-23 |
Family
ID=55490881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510886855.3A Withdrawn CN105412023A (en) | 2015-12-07 | 2015-12-07 | Frovatriptan succinate controlled-release granule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105412023A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107115325A (en) * | 2017-05-18 | 2017-09-01 | 青岛正大海尔制药有限公司 | Smooth capsules of a kind of butanedioic acid furan Luo Qu and preparation method thereof |
| CN107496380A (en) * | 2017-08-24 | 2017-12-22 | 青岛正大海尔制药有限公司 | Smooth sustained-release micro-spheres of a kind of butanedioic acid furan Luo Qu and preparation method thereof |
| CN110898037A (en) * | 2019-12-11 | 2020-03-24 | 正大制药（青岛）有限公司 | Frovatriptan succinate controlled-release capsule and preparation method thereof |
| CN111494344A (en) * | 2020-04-29 | 2020-08-07 | 正大制药（青岛）有限公司 | Dolichalciferol controlled-release particles |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006042249A2 (en) * | 2004-10-08 | 2006-04-20 | Neuromolecular Pharmaceuticals, Inc. | Methods and compositions for treating migraine pain |
| CN102123702A (en) * | 2008-06-16 | 2011-07-13 | 阿庇安实验室有限责任公司 | Composition and method of preparation of release systems for constant (zero-order) release of active agents |
| CN104800184A (en) * | 2015-04-22 | 2015-07-29 | 青岛正大海尔制药有限公司 | Slow-release tablet comprising succinate frovatriptan |
| CN104825400A (en) * | 2015-05-28 | 2015-08-12 | 中牧南京动物药业有限公司 | Florfenicol included controlled-release preparation and its preparing method and application |
-
2015
- 2015-12-07 CN CN201510886855.3A patent/CN105412023A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006042249A2 (en) * | 2004-10-08 | 2006-04-20 | Neuromolecular Pharmaceuticals, Inc. | Methods and compositions for treating migraine pain |
| CN102123702A (en) * | 2008-06-16 | 2011-07-13 | 阿庇安实验室有限责任公司 | Composition and method of preparation of release systems for constant (zero-order) release of active agents |
| CN104800184A (en) * | 2015-04-22 | 2015-07-29 | 青岛正大海尔制药有限公司 | Slow-release tablet comprising succinate frovatriptan |
| CN104825400A (en) * | 2015-05-28 | 2015-08-12 | 中牧南京动物药业有限公司 | Florfenicol included controlled-release preparation and its preparing method and application |
Non-Patent Citations (3)
| Title |
|---|
| 刘萍等: "琥珀酸福伐曲坦", 《中国新药杂志》 * |
| 张强: "《药剂学》", 31 January 2005, 北京大学医学出版社 * |
| 邓铁宏主编: "《中药药剂学》", 31 May 2006, 中国中医药出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107115325A (en) * | 2017-05-18 | 2017-09-01 | 青岛正大海尔制药有限公司 | Smooth capsules of a kind of butanedioic acid furan Luo Qu and preparation method thereof |
| CN107496380A (en) * | 2017-08-24 | 2017-12-22 | 青岛正大海尔制药有限公司 | Smooth sustained-release micro-spheres of a kind of butanedioic acid furan Luo Qu and preparation method thereof |
| CN107496380B (en) * | 2017-08-24 | 2019-10-01 | 正大制药（青岛）有限公司 | A kind of succinic acid furan Luo Qutan sustained-release micro-spheres and preparation method thereof |
| CN110898037A (en) * | 2019-12-11 | 2020-03-24 | 正大制药（青岛）有限公司 | Frovatriptan succinate controlled-release capsule and preparation method thereof |
| CN111494344A (en) * | 2020-04-29 | 2020-08-07 | 正大制药（青岛）有限公司 | Dolichalciferol controlled-release particles |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101574323B (en) | Migltol microcapsule tablet and preparation method thereof | |
| CN105412023A (en) | Frovatriptan succinate controlled-release granule and preparation method thereof | |
| CN107115325A (en) | Smooth capsules of a kind of butanedioic acid furan Luo Qu and preparation method thereof | |
| CN101884619B (en) | Zolpidem tartrate controlled-release pellet and preparation method thereof | |
| CN106963736A (en) | Dextromethorphan hydrobromide sustained-release dry suspensoid agent and preparation method thereof | |
| CN105434363A (en) | Topiroxostat controlled-release granule and preparation method thereof | |
| CN105919943A (en) | Clonidine hydrochloride controlled-release granule and preparation method thereof | |
| CN105496967B (en) | Ranitidine hydrochloride controlled release dry suspensoid agent and preparation method thereof | |
| CN101791298B (en) | Colon delivery tablet by using pectin / corn protein as coating | |
| CN101632661A (en) | Compound amoxicillin slow release dry suspension composition and preparation method thereof | |
| CN111214456A (en) | Voriconazole dry suspension and preparation method thereof | |
| CN104146977B (en) | A kind of pantoprazole sodium enteric tablet and preparation method thereof | |
| CN108283628B (en) | Anticancer medicine microcapsule preparation and its preparing method | |
| CN109925296B (en) | Coating method of traditional Chinese medicine pellets | |
| WO2023168316A1 (en) | Enteric coated dry powdered cannabinoid formulations | |
| US20240041782A1 (en) | Oral Capsule Cannabinoid Formulations | |
| CN105412039A (en) | Frovatriptan succinate controlled-release tablet and preparation method thereof | |
| CN114681406B (en) | Carilazine long-acting slow-release microsphere and preparation method thereof | |
| CN106619646B (en) | A kind of preparation method of tegafur, gimeracil and oteracil potassium composition | |
| CN103222964A (en) | Orlistat oral preparation and preparation method thereof | |
| CN110898037A (en) | Frovatriptan succinate controlled-release capsule and preparation method thereof | |
| CN102872027B (en) | Preparation of medicine granules for treating asthma and pneumonopathy and preparation of suction type compound aerosol of granules | |
| CN108403661B (en) | Medicinal microcapsule preparation for treating non-small cell lung cancer and preparation method thereof | |
| CN111821266A (en) | Taurine sustained-release composition and preparation method thereof | |
| CN116725985B (en) | Micropill combined urapidil sustained-release capsule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160323 |
|
| WW01 | Invention patent application withdrawn after publication |